COLUMBUS, Ohio – The division of gastrointestinal oncology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC-James) continues to expand with the appointment of Dr. Tanios Bekaii-Saab (43206) as medical director, and the recruitment of Dr. Kyle Perry (43026) and Dr. Jeffrey Rose (43209).
“The promotion of Dr. Bekaii-Saab, coupled with the added expertise of Drs. Perry and Rose, will further strengthen the gastrointestinal cancer program at The James that has shown continuous growth in patient volume for the past six years,” said Dr. Michael Caligiuri, director of Ohio State’s Comprehensive Cancer Center and chief executive officer of The James.
Bekaii-Saab is a physician-researcher who specializes in treating patients with gastrointestinal malignancies including pancreatic, liver and colon cancers. An assistant professor in Ohio State’s College of Medicine, he also has served as the chairman of gastrointestinal cancer disease specific committee at OSUCCC-James since 2003.
Perry, who is an assistant professor of surgery in Ohio State’s College of Medicine, joined the gastrointestinal surgery division where he will focus on gastric and esophageal cancer surgery. Perry received his medical degree from Temple University School of Medicine and completed his residency in general surgery at Rush University Medical Center. He completed his fellowship in minimally invasive surgery as well as graduate level course work in epidemiology at Oregon Health and Science University.
Rose, who is an assistant professor of medicine in Ohio State’s College of Medicine, joined the division of medical oncology, where he will focus on treating gastrointestinal cancers. Rose graduated from the University of Nebraska College of Medicine and completed his residency in internal medicine at Wake Forest University Baptist Medical College, where he was named chief resident. He completed his fellowship in hematology and oncology at the University of Iowa Hospital and Clinics.
The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.# # #
Medical Center Communications